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Abstract 26 
Background and objectives 27 
The guidelines from the British Thoracic Society (BTS) regarding the investigation of unilateral 28 
pleural effusions recommend computed tomography (CT) in exudates.  29 
We decided to investigate if clinicians follow BTS guidelines´ recommendations with respect to CT 30 
in patients with unilateral pleural effusions. Secondly, to investigate the diagnostic consequences of 31 
following and not following this recommendation. 32 
 33 
Methods 34 
The study was a retrospective, non-randomized study including consecutive patients referred to our 35 
tertiary centers in 2013-2016 because of unilateral pleural effusion. Patients undergoing chest CT for 36 
unilateral pleural effusion of unknown cause after thoracentesis and chest x-ray were included. 37 
Patients were categorized as having pleural exudates or transudates, according to Light’s criteria, if 38 
applicable. We registered use of CT, and calculated diagnostic values. 39 
 40 
Results 41 
In total, 323 of the 465 included patients underwent CT (70%). CT was performed in the majority of 42 
patients not having an exudate (transudates: n=40; 54%; Light’s criteria not assessed: n=111; 67%). 43 
18F-FDG PET/CT without prior CT was performed in 32 patients with an exudate (56%).  44 
The sensitivity of a non-guideline supported CT (70%) was significantly higher compared to a 45 
guideline supported CT (47%), p-value<0.045.  46 
The post-test probability of a positive guideline-supported CT (LR positive 3.26) for a later diagnosis 47 
of thoracic malignancy increased the probability from 25% to 52%. A negative CT (LR negative 48 
0.62) decreased the probability to 17%.  49 
For a non-guideline-supported CT the numbers were (LR positive 3.42) 53% and (LR negative 0.38) 50 
 3 
11%, respectively. 51 
 52 
Conclusion 53 
Clinicians appear not to follow BTS guidelines when deciding to perform chest CT. The relevance of 54 
this deviation is supported by the superior sensitivity of CT non-guideline supported CT.  55 
Overall, CT is associated with suboptimal sensitivity and negative predictive values for the diagnosis 56 
of thoracic malignancy. 57 
 58 
 59 
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Introduction 74 
Identifying the etiology of a unilateral pleural effusion is a clinical challenge. More than 50 different 75 
causes have been described, including both localized pleural diseases and systemic conditions (1). 76 
The incidence of malignant disease is 20-70% depending on the study population (2-5). According to 77 
the guideline by the British Thoracic Society (BTS), initial work-up of a unilateral pleural effusion 78 
includes a medical history, physical examination and a review of prescribed and over-the-counter 79 
drugs (1). In unsolved cases, the guideline suggests a chest x-ray and aspiration of pleural fluid for 80 
cytology and biochemical characterization according to Light’s criteria (1, 6), see Figure 1. If the 81 
fluid is not a transudate and fluid analysis and clinical features are not diagnostic, it is recommended 82 
to perform a contrast enhanced computed tomography (CT) scan of the thorax.  83 
The recommendation of CT is based on five studies (1): one study on empyema (7), two studies on 84 
pleural thickening (8, 9), one summary article mainly including studies on patients with empyema 85 
and pleural thickening (10), and one study including patients with pleural effusions (11).  86 
In addition, it has not previously been investigated how often the guidelines’ recommendation of CT 87 
is followed, which is in contrast to what is known about other guidelines (12-14). 88 
On this background, we set out to investigate whether 1) clinicians follow BTS guidelines´ 89 
recommendations with respect to CT in patients with unilateral pleural effusions and 2) the 90 
diagnostic consequences of following, respectively not following this BTS guidelines. 91 
 92 
93 
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Materials and Method 94 
 95 
Ethics 96 
The study was a retrospective observational study, without randomization or study-specific 97 
interventions. Such types of studies are exempt from approval by the local Research Ethics 98 
Committee according to Danish legislation (ID 17-000048). The study was approved by the Danish 99 
Data Protection Agency (REG-147-2017) and was reported to The Danish Patient Safety Authority. 100 
 101 
Study design and Participants 102 
In this retrospective cohort study, we identified all adult patients consecutively referred with 103 
unilateral pleural effusion to the Department of Pulmonary Medicine at Naestved and Roskilde 104 
hospitals (tertiary referral centers), Region Zealand, Denmark, from January 2013 to December 105 
2016. Information on patient demographics, clinical and para-clinical information and investigations 106 
were retrieved from the hospital database.  107 
For the purpose of a sub-analysis on the diagnostic value of CT, patients having had both 108 
thoracentesis, chest x-ray and CT of the chest performed, but no known malignancy in the thorax, 109 
were selected. All patients were followed for a minimum of 12 months. 110 
 111 
Outcome of BTS guidelines 112 
According to the diagnostic algorithm in the BTS guideline, pleural fluid biochemical analysis 113 
should be performed when patients are referred to a chest physician, see Figure 1.  114 
1. We registered in how many cases the pleural fluid was classified as a transudate or exudate 115 
according to Light’s criteria (6).  116 
2. If the pleural fluid was classified as a transudate, the cause should be treated. We registered 117 
in how many patients CT was performed. 118 
 6 
3. If the pleural fluid was classified as an exudate, two diagnostic approaches exist: if fluid 119 
analysis and clinical features has given a diagnosis, then the patients should be treated 120 
appropriately. Secondly, if fluid analysis and clinical features has not given a diagnosis, a CT 121 
should be performed. Therefore, we registered patients not investigated with a CT and if the 122 
physicians’ provisional diagnosis were correct. If a CT was performed, we calculated 123 
diagnostic values as stated below. 124 
 125 
Classification of the pleural fluid 126 
Light’s criteria (6) were used. The pleural effusion was considered an exudate if one or more of the 127 
following criteria were met:   128 
1. Pleural lactate dehydrogenase/serum lactate dehydrogenase ratio > 0.60  129 
2. Pleural protein/serum protein ratio > 0.50 130 
3. Pleural lactate dehydrogenase > 2/3 of normal upper limit.  131 
The pleural effusion was considered a transudate if neither of these criteria were met.   132 
 133 
CT 134 
All patients underwent contrast-enhanced CT (CT) of the chest and upper abdomen. CT was 135 
performed using standard protocols: before CT imaging (Philips Brilliance (multislice) 64 or iCT 136 
256, Best, Netherlands), 100 ml Optiray 300 mg I/ml or 100 ml Iomeron 350 mg I/ml was injected 137 
intravenously (flow rate 4ml/sec) followed by a bolus of 10 ml isotonic NaCl. All examinations were 138 
read by two radiologists and a report was written after having reached consensus (routine procedure).   139 
 140 
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Classification of results 142 
Cytological examination of the pleural fluid, chest x-ray and CT findings were categorized as below. 143 
The investigations were classified blinded to results of later examinations performed and the clinical 144 
course. 145 
 146 
Cytological examination of pleural fluid 147 
All pleural fluid cytological examinations in Denmark are recorded at The Danish Pathology 148 
Register, a national database including data from all pathological examinations in Denmark since 149 
1990 (15). We registered if malignant cells were found during routine examination. 150 
 151 
Chest x-ray 152 
The classification of each chest x-ray was based on the routine description as follows: 153 
 X-ray not suspicious for malignancy 154 
 X-ray suspicious for malignancy 155 
If any of the following was found: hilar enlargement or consolidation or atelectasis described 156 
as suspicious for malignancy, solitary nodules > 20mm, multiple nodules, any masse(s) single 157 
or multiple, and pleural opacities. 158 
 X-ray inconclusive 159 
Patients with an inconclusive x-ray was included in the analysis of the diagnostic value of CT. 160 
 161 
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CT results 163 
The classification of each CT-scan was based on the routine scan report as follows:  164 
 CT not suspicious of malignancy  165 
 CT suspicious of malignancy: 166 
If any of the following was found: circumferential pleural thickening, nodular pleural 167 
thickening, parietal pleural thickening > 1 cm or mediastinal pleural involvement and/or 168 
showed parenchymal abnormalities (nodules >8 mm) (8, 16).  169 
 CT inconclusive: 170 
None of the above. 171 
An inconclusive CT was classified after a worst-case scenario thus as incoherent with the final 172 
diagnosis (17). 173 
 174 
The final diagnosis 175 
A final diagnosis of malignancy was based on a multi-disciplinary team decision and tissue biopsies 176 
(e.g. transthoracic needle aspiration/biopsy or thorascopy).  177 
We searched electronic medical records including the Danish Pathology Register (15) for new 178 
diagnoses of malignancy within 12 months after thoracentesis.   179 
A non-malignant, final diagnosis was defined as no pathoanatomical findings of malignancy within 180 
one year from thoracentesis. 181 
 182 
183 
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Statistics 184 
Data were presented as frequencies and/or median and range. Based on a classification of the 185 
suggested diagnoses as true-positive (TP), true-negative (TN), false-positive (FP), false-negative 186 
(FN), we calculated the sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood 187 
ratio (LR-), positive predictive value (PPV), negative predictive value (NPV), and diagnostic 188 
accuracy ((TP+TN)/(TP+FP+TN+FN)).  189 
In case of equivocal findings on CT a worst-case scenario was defined as: if the final diagnosis was 190 
malignant, the CT was categorized as not suspicious of malignancy and if the final diagnosis was 191 
non-malignant, the CT was categorized as suggestive of malignancy. 192 
Categorical data were analyzed using Chi2-test or Fishers Exact test, were appropriate. Mann-193 
Whitney’s test (Wilcoxon rank-sum test) was used for continuous data. Bayesian statistics were used 194 
to calculate the post-test probability of malignancy. 195 
Data were analyzed using STATA (StataCorp LLC, Version 15.0, College Station, Texas, USA).  196 
 197 
Results 198 
Figure 2 depicts the flow of patients. In total, 465 patients were eligible presenting with a unilateral 199 
pleural effusion of unknown cause after baseline examination (chest X-ray, and pleural fluid 200 
cytology and culture). Median age was 74 (range 22-99) years, 167 (35%) were females, and CT was 201 
performed in 323 patients (70%).  202 
 203 
204 
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Adherence to BTS’ guidelines with respect to CT 205 
Measurement of pleural lactate dehydrogenase and/or protein was absenting in 165/465 patients 206 
(36%). Of these, 111 patients underwent CT (67%). In 74/465 patients (15%) the pleural fluid was 207 
classified as a transudate regardless hereof, 40 patients (54%) underwent a CT. 208 
The remaining 226/465 patients (49%) were classified as having an exudate, which in 23 patients 209 
was diagnosed as secondary to specific, non-malignant diseases (most often congestive heart failure 210 
or renal failure). CT was performed in 172 of the remaining 203 patients (85%). 211 
Of the 323 patients who underwent CT, the referral was in accordance with BTS guidelines in 172 212 
patients (53%) (Figure 1) (1). 213 
Patients in whom Light’s criteria were not applied, were significantly younger and more often 214 
diagnosed with malignancy, but we found no difference in gender and the use of CT, see Table 1. 215 
Overall, there was no difference in age, gender and number of malignancies between patients with 216 
and without CT, Table 2. 217 
 218 
Patients not classifiable according to Light’s criteria 219 
Out of 465 patients, 165 had a pleural effusion not classified according to Light’s criteria, see 220 
Figures 1 ()  and 2. Forty-five patients (27%) were diagnosed with a new malignancy and 17 221 
patients (10%) were diagnosed with malignant pleural effusion from a previously known primary 222 
cancer; in total 62 patients (38%) with: lung cancer (n=36; 58%), malignant pleural mesothelioma (n 223 
=8; 13%), breast cancer (n =5; 8%), malignant lymphoma (n =4, 7%), esophagus cancer (n =2; 3%), 224 
laryngeal cancer (n =2, 3%) and five patients (8%) with either malignant melanoma, gallbladder 225 
cancer, liver cancer, tongue cancer or cancer of unknown primary.  226 
Six patients (4%) were lost to follow-up. 227 
228 
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Pleural transudate not investigated with CT 229 
Following guidelines, 34/465 patients had a pleural transudate and a CT was not performed, see 230 
Figures 1 () and 2. Of these, two patients (6%) were diagnosed with lung cancer with pleural 231 
metastases and two patients (6%), who had previously received intended curative treatment for non-232 
metastatic lung cancer, had recurrence with pleural metastases. 233 
One patient (3%) were lost to follow-up. 234 
 235 
Pleural transudate investigated with CT 236 
In spite of the guidelines recommendations, 40/465 patients with a pleural transudate underwent CT, 237 
see Figures 1 () and 2. Of these, six patients (13%) were diagnosed with malignancy: lung cancer 238 
(n=4; 66%), malignant pleural mesothelioma (n=1; 17%) and bladder cancer (n=1; 17%).  239 
CT was performed due to suspected malignancy in 22/40 patients (60%), including 12 with known, 240 
non-pleural malignancy. CT was performed in 10/40 patients (40%) due to suspected non-malignant 241 
causes (e.g. empyema, pulmonary embolism).  242 
Four patients (9%) were lost to follow-up. 243 
 244 
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Pleural exudate investigated with a CT 246 
Following the guideline recommendations, 172/465 patients with a pleural exudate underwent CT, 247 
see Figures 1 () and 2. Of these, 21 patients (12%) were diagnosed with a new malignancy and 11 248 
patients (6%) were known with a non-pleural malignancy prior to referral, in total 32 patients (19%) 249 
with: lung cancer (n=13; 41%), malignant pleural mesothelioma (n=6; 19%), breast cancer (n=6; 250 
19%), malignant lymphoma (n=3; 9%), and 4 patients (12%) with either renal cancer, gastric cancer, 251 
tonsillary cancer and thymoma.  252 
Of the remaining 140 patients without a diagnosis of malignancy (84%), 22 (16%) died during 253 
follow-up.   254 
 255 
Pleural exudate not investigated with a CT 256 
Despite having a pleural exudate, 55/465 patients did not undergo a CT, see Figures 1 () and 2. Of 257 
these 11 patients (20%) were diagnosed with a new malignancy, and 2 patients were known with 258 
non-pleural malignancy; in total 13 patients (24%) with: lung cancer (n=3; 23%), lung cancer and 259 
malignant lymphoma (n=1), malignant pleural mesothelioma (n=3; 23%), ovarian cancer (n=2; 15%) 260 
and 4 (31%) with one of the following: breast cancer, kidney cancer, malignant lymphoma and 261 
pancreatic cancer.  262 
18F-FDG PET/CT without prior CT was performed in 32/55 patients (56%) and all 13 malignant 263 
cases were in this group. 264 
The 23 patients (44%) who were judged to have non-malignant cause of the pleural effusion were 265 
managed appropriately and none developed malignancy during the follow-up period.  266 
Nine patients (39%) died during follow-up. 267 
 268 
269 
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Diagnostic value of guideline-based CT (exudative pleural effusions) 270 
A total of 172 patients with exudative pleural effusions underwent a CT. In one patient, the CT was 271 
performed at another location and it was not possible to retrieve CT images or scan report, leaving 272 
171 for this analysis. The CT was classified as inconclusive in 10 patients (6%) and they were 273 
included as specified under methods. In total, 32/172 patients (19%) were diagnosed with 274 
malignancy during the study period.  275 
Overall, CT was suggestive of malignancy in 35 patients (21%), and 15 of these (43%) were 276 
diagnosed with malignancy. The sensitivity was 47% [29-65%] and negative-predictive value was 277 
88% [83-91%], see Table 3. 278 
In patients with thoracic malignancies, the CT was suggestive of malignancy in 28 patients (17%), 279 
and of these, 8 (29%) were diagnosed with malignancy; the sensitivity was 42% [20-67%] and 280 
negative predictive value was 92% [88-94%], see Table 3. 281 
In patients with extrathoracic malignancy, the CT was suggestive of malignancy in 27 patients 282 
(18%), and of these, 7 (26%) were diagnosed with malignancy. The sensitivity was 54% [25-81%] 283 
and negative-predictive value was 95% [92-97%], see Table 3. 284 
 285 
Diagnostic value of non-guideline-based CT 286 
Overall 151 patients were included in the analysis; transudates n=40 and not classifiable according to 287 
Lights criteria n=111. The CT was classified as inconclusive in seven patients (6%) and they were 288 
included as specified under methods. In total, 43 patients (29%) were diagnosed with malignancy 289 
during the study period. 290 
Overall, The CT was suggestive of malignancy in 52 patients (34%), and of these, 30 (62%) were 291 
diagnosed with malignancy. The sensitivity was 70% [54-83%] and negative-predictive value was 292 
87% [81-91%], see Table 3.  293 
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In patients with thoracic malignancies, the CT was suggestive of malignancy in 43 patients (31%), 294 
and of these, 21 (49%) were diagnosed with malignancy; sensitivity 68% [49-83%] and negative 295 
predictive value 90% [84-94%], see Table 3. 296 
In patients with extrathoracic malignancy, the CT was suggestive of malignancy in 31 patients 297 
(21%), and of these, 9 (29%) were diagnosed with malignancy. The sensitivity was 75% [43-95%] 298 
and the negative-predictive value was 97% [91-99%], see Table 3. 299 
 300 
The diagnostic value of guideline versus non-guideline supported CT 301 
The sensitivity of a non-guideline supported CT was significantly higher compared to a guideline 302 
supported CT (70% resp. 47%), p-value<0.045. There was no statistical difference in specificity.  303 
 304 
Clinical application 305 
According to the Bayesian method, estimates of the post-test probability of a malignant unilateral 306 
pleural effusion in patients who underwent a CT is a function of disease prevalence (pretest 307 
probability). The disease prevalence in our population was 25%, which equals other findings in 308 
Europe (3, 4). 309 
In all patients with CT performed according to the BTS guideline, the findings of a positive CT (LR 310 
positive 3.26), would increase this probability to 52% [47-58%], whereas a negative result (LR 311 
negative 0.62) would decrease the probability of malignancy to 17% [15-19%].   312 
In all patients with CT not performed in accordance with the BTS guideline, the findings of a 313 
positive CT (LR positive 3.42) would increase this probability to 53% [49-57%], whereas a negative 314 
result (LR negative 0.38) would decrease the probability of malignancy to 11% [9-13%].  315 
 316 
317 
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Discussion 318 
This is the first study to investigate if patients with unilateral pleural effusion are investigated with 319 
CT according to the BTS guideline (1). We found that in almost half of the patients in our study 320 
population (47%), the decision of performing CT was not in agreement with the BTS 321 
recommendations (1). E.g. 54% of patients with pleural transudates had undergone CT, which is not 322 
recommended by the guideline. Furthermore, the sensitivity of a non-guideline supported CT was 323 
significantly higher than a guideline-supported CT. 324 
The sensitivity of CT for predicting malignancy in pleural effusions have been investigated in five 325 
studies, yet none reported data on unilateral effusions in isolation  (11, 18-21). 326 
Our findings are in accordance with three of the five above studies (18, 19, 21). The sensitivity was 327 
higher in two studies (86% and 92%, respectively) (11, 20). Patients included in these studies were 328 
highly suspicious for malignancy or referred to thoracoscopy, and the incidence of malignancy was 329 
higher compared to our study (80% and 68%, respectively) (11, 20). These patients may have had a 330 
higher level of clinical disease stage, resulting in pathoanatomical changes which can be more easily 331 
identified on CT (i.e. lower rate of false negatives). We found an incidence of malignancy of 25%, 332 
which is in accordance with previous findings of approximately 20% (3, 4).  333 
This difference in study population could also explain the superior specificity found by Traill et al. 334 
(100%) (11). 335 
Two studies found a specificity of 93% and 92%, respectively (19, 21). In one of the studies, an 336 
advances score was calculated based on logistic regression findings (21). This could result in fewer 337 
false positive findings (not specified), and thus a superior specificity (21).  338 
In the last study (21), it is uncertain what caused the difference in specificity, the study population is 339 
identical, however, the type of CT used, how the images were analyzed, and how the findings were 340 
classified was not stated (19). 341 
 342 
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Thoracic ultrasound has a high sensitivity for the detection of pleural fluid (100% if >100 ml (22)), 343 
and is, in addition, used for image-guided techniques (e.g. tissue biopsies, thoracentesis, and chest 344 
tube insertion) (23). Thoracic ultrasound was found to have a sensitivity of 73% and specificity of 345 
100% for predicting malignancy in patients with a pleural effusion, the corresponding numbers for 346 
CT were sensitivity 97% and specificity 89% (24). CT correctly identified 32/33 patients with 347 
malignant causes compared to 26/33 for thoracic ultrasound (24). However, CT identified two 348 
patients as false positive, whereas thoracic ultrasound identified all patients with benign disease (24). 349 
 350 
The superior sensitivity of non-guideline supported CT (compared to guideline-supported), could be 351 
explained by physicians not measuring pleural LDH or protein in patients with a high suspicion of 352 
malignant disease. Several clinical features can predict malignancy in patients with pleural effusions 353 
referred to thoracoscopy (20). Alternatively, the differentiation into exudates and transudates do not 354 
assist in the decision of performing CT.  355 
The incidence of malignancy in patients with pleural exudates is approximately 30% (4, 19) and in 356 
pleural transudates 10% (25, 26). Because of this, among others, it has been suggested to perform 357 
intensive investigations in all patients presenting with a unilateral pleural effusion (19, 27). 358 
 359 
In the daily clinical work up, the clinicians base the handling of the patients on the descriptions of 360 
the CT from the department of radiology. It was not the aim of this study to examine inter- and intra-361 
observer variation among different assessors (17). The aim was solely to investigate what comes 362 
from following the BTS guidelines in everyday clinical life. 363 
A strength of the study is, that it is the first study investigating the use of the BTS guidelines’ 364 
recommendations in the clinical work up of unilateral pleural effusions: i.e. including unselected, 365 
consecutive patients with a unilateral pleural effusion regardless of the presence of pleural 366 
abnormalities (e.g. thickening or nodules) and excluding patients suggestive of malignancy at either 367 
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pre-CT pleural fluid cytology or chest x-ray (11, 18, 21). Furthermore, our study it is the largest 368 
study investigating the value of CT in unilateral pleural effusions and exudates, and the third largest 369 
when including studies on pleural lesions and both bilateral and unilateral pleural effusions (18, 21).  370 
Overall, approximately two-thirds of the patients were investigated with a CT, independent of the 371 
classification into transudates and exudates. In addition, the sensitivity of a non-guideline CT was 372 
superior compared to a CT performed in accordance with the BTS guideline. Having in mind that 373 
approximately 10% of the patients with a pleural transudate were diagnosed with a malignancy, 374 
physicians must consider if a CT should be performed in this setting.  375 
One third of the patients (n=25; 33%) who underwent CT and had a malignant cause, were found to 376 
have an extrathoracic malignancy. The guideline recommends a contrast-enhanced chest CT (1), 377 
however, future patients might benefit from performing CT of the thorax and abdomen. Future 378 
studies need to evaluate, whether this will increase the diagnostic value of CT. 379 
In general, a good diagnostic test provides a LR+ >10 and a LR <0.1 (28, 29). We found a LR+ of 380 
3.42 and LR of 0.38, which is indeed concerning because it may lead to a high number of 381 
superfluous investigations in a substantial number of patients and a considerable risk of missing 382 
malignancy in others.  383 
We speculate that the addition of PET-CT would increase the positive predictive value and 384 
sensitivity. One retrospective study found a higher sensitivity and equal specificity of FDG PET/CT 385 
compared to CT alone in distinguishing benign from malignant pleural effusions (30). On the 386 
contrary, a meta-analysis concluded that PET-CT should not be used as a routine examination 387 
because PET-CT did not change the probability of malignancy sufficiently (31). Both studies 388 
included patients with bilateral pleural effusions, and the meta-analysis also included patients with 389 
known thoracic malignancies and pleural lesions.  390 
In our study, malignant pleural mesothelioma, lung cancer and malignant lymphoma were 391 
predominant, and PET-CT can rule out malignancy in most solitary pulmonary nodules and pleural 392 
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lesions due to high sensitivity (32, 33).  393 
A limitation of the study is the retrospective design, which unavoidably implies a risk for selection 394 
bias.  395 
 396 
Conclusion 397 
Clinicians appear not to follow BTS guidelines when deciding to perform chest CT, the relevance of 398 
this deviation is supported by the superior sensitivity of CT non-guideline supported CT.  399 
However, overall, CT is associated with low sensitivity and specificity for the diagnosis of thoracic 400 
malignancy. 401 
 402 
403 
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Figure 1 – Diagnostic algorithm from Investigations of a Unilateral Pleural Effusion in Adults: 486 
British Thoracic Society Pleural Disease Guideline 2010 487 
 488 
With permission from the authors. 489 
 490 
 491 
Figure 2 – Patient flow 492 
 493 
Dotted lines and symbols () refer to respective steps in diagnostic algorithm Figure 1 494 
 495 
Table 1 – Comparison of patients with respect to the use of Light’s criteria 496 
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Table 2 – Comparison of patients with respect to the use of CT 499 
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Table 3 – Diagnostic value of CT502 
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